Classical chemotherapy has no chance to help in Tamara’s situation. Her final hope is an innovative immune therapy from the USA. The agent of this immunotherapy is called Durvalumab and the treatment takes place at the NCT in Heidelberg. Checkpoint inhibitors help to demask the cancer, so that the patient’s own immune system recognizes it for what it is and is able to fight it. Unfortunately, her health insurance doesn’t yet pay for this. In addition, she gets so-called PARP inhibitors for her BRCA1-genetic mutation. This combined therapy is currently held to be the most effective way to treat spreading TNBK. This is an important opportunity that Tamara simply has to use.